Vir: New Data Evaluating VIR-2218 and VIR-3434 for Functional Cure for Chronic Hep B

  Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals –

– Preliminary data to-date show that 30.8% of participants receiving 48 weeks of VIR-2218 plus pegylated interferon alpha achieved HBsAg seroclearance with anti-HBs seroconversion by end of treatment –

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in two oral presentations, both of which were selected for inclusion in the “Best of the Liver Meeting” summary, a poster and a late-breaking poster presentation. The “Best of the Liver Meeting” designation underscores the strength of Vir’s broad hepatitis portfolio, which is addressing both HBV and hepatitis D virus (HDV).

In one oral presentation, new preliminary data from an ongoing Phase 2 trial demonstrated that 30.8% of participants receiving 48 weeks of VIR-2218, an investigational small interfering ribonucleic acid (siRNA), initiated concurrently with pegylated interferon alpha (PEG-IFN-α), achieved HBsAg seroclearance with anti-HBs seroconversion. Additionally, 48 weeks of VIR-2218 plus PEG-IFN-α provided greater reductions in hepatitis B surface antigen (HBsAg) (mean decrease of -2.9 log10 IU/mL) compared to VIR-2218 alone or with shorter regimens of the combination. No new safety signals were identified.

https://finance.yahoo.com/news/vir-biotechnology-presents-data-evaluating-153500701.html